One-Stop Shopping (setravis)

[setravis]

TOP NEWS GAINERS:

SYM      CLOSE     %GAIN     VOLUME                         NEWS

BEIC     $0.090     350.00     6,591,500        Increased Production of TISCO Expected to Increase Market Demand

FICC     $4.980     91.54       16,973,200      Definitive Merger Agreement w/C-BASS and Radian Group

IWRS    $1.010     77.19             21,600       To Acquire 25 Claims Barkerville-Quesnel Area of British Columbia

BSQR    $4.520     29.14       2,990,600        Q4 EPS 7c vs (3c) EPS +333% Y/Y

BMJ       $8.910     25.85           107,900       Q3 EPS $1.65 vs $1.5 EPS +10% Y/Y; Guidance Comments

HURC    $42.750   21.59       1,058,300        Q1 EPS 84c vs 48c Beats 66c Est

STMP    $16.980   18.74        2,621,300        First Albany Ups to Buy from Neutral; Sets Tgt @ $19; Analyst Notes

ESST     $1.270     17.59           985,000       Announces the Sale of HD Assets and Technologies; Appoints New Board Member

CNTF     $9.850    17.12        1,205,000        Brean Murray Ups to Buy from Hold; Sets Tgt @ $11; Analyst Notes

AVSR     $1.800    14.65              94,500       Agrees to Patent Settlement Litigation w/Tandberg

IEAM     $5.720    11.07            619,500       Q2 EPS (19c) vs (12c) EPS -58% Y/Y; Guidance Comments

LTXX     $6.240    10.44        2,144,600        Friedman Ups to Outperform from Mkt Perform; Ups Tgt to $7 vs $4.5; Analyst Notes

BWLD   $54.810   9.66         2,124,800        Q4 EPS 66c vs 38c Beats 53c Est

[setravis]

Why This Stock Is a Winner.......

If you could wave a magic wand and bestow just one characteristic on all of your investments, what would it be? (Besides the ability to print money, that is.)

I began thinking about this after reading Tom Gardner's "A 25-Bagger in Five Years," where he identified three things that give a company the chance to achieve outsized gains over the years -- like 25-baggers that turn $5,000 into $125,000. Of the three he mentions, one characteristic is most important to me: A high level of insider ownership.

Why it matters
But this makes sense, right? Think about any of your major personal investments:

1. You are a stockholder, with a good deal of your wealth riding on this company's performance.

2. Founders and managers with high levels of ownership also have their wealth riding on the company's performance.

3. They are doing everything they can to increase the long-term value of their stock.......which is also your stock.

Having a wonderful time ...
With their reputations, their livelihoods, and their careers on the line, you can be fairly sure that these managers and board members are motivated to do what's best for the company. It's like having someone on the inside, working for you. Every day.

What is the opposite of that?
Businesses in which management has very little tied up in company stock. Where actions may be motivated by things that actually harm the stock's performance, like office politics, power plays, or working more with an eye on the clock (is it 5:00 yet?) than on improving the business model. Or, even worse, management that rewards itself with high salaries and bonuses that have nothing to do with outstanding performance.

Now, don't be chagrined if you find that some of your larger holdings have a low percentage of insider ownership. For example, General Electric (NYSE: GE) is only 0.12% owned by insiders. Altria (NYSE: MO) sports 0.18% insider ownership. Their sheer size makes it awfully tough for anyone to own a significant share of the entire business.

But smaller companies are a much different story. In small-cap land, CEOs and managers with high levels of ownership are much more likely to rise above the mediocrity and work toward the common goal of great stock performance.

For instance ...
I ran a screen for some companies with high insider ownership, but I went a bit beyond that. The following businesses also have strong sales and earnings growth, high margins, and high returns on equity.......A potentially winning combination.



Company        Insider          Sales            EPS          Net          ROE*
                   Ownership      Growth*      Growth*   Margin

GRMN              43%              73%             65%       29.0%      37.9%

GES                 62%              27%           105%       10.4%      34.2%

HERO              24%             113%           242%      34.6%      39.0%

OXPS              31%              45%             46%       38.4%      47.9%

AEIS               21%              26%            470%       21.5%     28.4%

Insider ownership, especially in smaller companies, is one positive indicator in the quest for tomorrow's multibaggers. There are many more, of course, but insider ownership is one of the core variables to screen for.

[setravis]

Outstanding performers ripe for inclusion in your portfolio or watch list........

Symbol       Last        Change           Volume                   Event
BID             41.02      1.04              2,370,530       Record Price Break Out
SCS            20.18       0.19             1,869,500       Record Price Break Out
CHTT          57.95       4.60             1,569,343       Record Price Break Out
STKL           11.97       0.30             1,841,656       Record Price Break Out
OEH            58.59      3.55              3,236,000            Trending Up
RHT            24.15       0.32             1,944,400             Trending Up
SIGM          31.02       0.57             2,620,836             Trending Up
STKL          11.97        0.30             1,841,656             Trending Up
JEC            47.27        0.71             1,184,200             OverSold
EMC           13.53        0.27             26,244,304        Analyst Upgrade
PG             63.84        0.89             14,690,720        Analyst Upgrade
IMCL          33.88       1.25              3,965,299          Analyst Upgrade
ATW          56.18        0.89              400,300            Recommendation!
NFI            6.26          0.06              7,542,761             Favorite!
NUAN        16.20        0.37              9,557,891             Top Pick!
TSL           45.43        3.45              1,335,900             Top Pick!

[setravis]

Underperformers ready for a tumble,
If you like to play the short side.



Symbol        Last          Change              Volume                 Event
AMD            13.35         -0.25              28,363,267       Record Price Low
WMG          16.54          -0.66              1,060,400         Record Price Low
PPCO         10.13          -0.14              1,619,266         Record Price Low 
CLC            30.62         -2.87               2,249,000           Percent Loser
MOT           17.50         -1.24             190,691,229         Percent Loser
INTU          27.54         -2.46               11,383,320         Percent Loser
MSD           10.59          -0.11                 122,500          Trending Down
IM              19.49          0.04                  697,600            OverBought
LPL             17.87         -0.34               1,014,400           OverBought
BOBJ           37.16         -0.38               1,594,780           OverBought
AUY            14.59         -0.28                9,630,900       Analyst Downgrade
MOT           17.50         -1.24              190,691,229     Analyst Downgrade
LLTC          33.50         -0.22                 4,845,778      Analyst Downgrade
MEOH        22.60         -0.28                  658,036        Analyst Downgrade
QID            52.52         0.41                12,407,917          Top Short!
FCX           61.91         -0.66                16,459,649          Top Short!
BIDU         102.59        1.63                1,942,692            Favorite Short!
CFC          36.38         -0.57                 8,519,692           Favorite Short!

[setravis]

Outstanding performers ripe for inclusion in your portfolio or watch list.
It's One-Stop shopping for investment ideas.......


Symbol       Last          Change            Volume                               Event
EMC          15.22          0.46             74,086,838                 Record Price Break Out/
                                                                                                Earnings Surprise

PEP           65.80          1.24             12,026,572                 Record Price Break Out

HLTH         16.15          0.43              6,452,418                  Record Price Break Out

NTRS         64.27          1.73              2,283,217                  Record Price Break Out

KFT           32.90          0.14             18,776,147                        Trending Up

ODP          36.18          0.07               2,479,100                         Trending Up

QSFT        17.42          0.52                1,571,889                        Trending Up

SSCC       11.98           0.00               4,788,307                         Trending Up

ESLR        11.90          -0.17             14,189,673                    Earnings Surprise

BSX         16.10           0.10              17,778,442                     Analyst Upgrade

MCO        68.40          2.68               11,226,400                     Analyst Upgrade

COST       55.59          1.20                5,958,491                      Analyst Upgrade

CMI         75.19          0.23                1,124,700                           OverSold

PHI         52.27          1.13                   413,900                           OverSold

SBNY      32.29          0.67                   201,139                            OverSold

[setravis]

Underperformers ready for a tumble,
If you like to play the Short Side........


Symbol            Last              Change                Volume                              Event

MU                  10.95            -0.12                 28,842,042                    Record Price Low
SDS                 54.77            -0.23                  1,837,302                     Record Price Low
CLWR              17.75            -0.86                  6,131,060                    Record Price Low
FBTX               15.21             -0.28                  1,236,819                    Record Price Low
FIC                 37.08             -3.47                  6,121,830                      Percent Loser
KEY                 36.36            -2.22                   7,516,580                      Percent Loser
AMTD              15.31            -1.56                  31,843,006                     Percent Loser
PALM              17.10              0.01                   2,945,207                    Trending Down
DVR                15.12            -0.13                       347,500                      OverBought
KBR                21.42            -0.48                    6,494,998                      OverBought
KNOT             22.73             -0.28                      489,337                       OverBought
PMTC             19.09             -0.18                   1,364,012                       OverBought
TER                16.35             -0.17                   7,209,798                 Analyst Downgrade
VLO               65.30             -1.61                  16,128,320                 Analyst Downgrade
JASO              24.93             -3.26                   5,596,992                 Analyst Downgrade
NVLS             32.09             -1.15                    6,295,285                 Analyst Downgrade

[Ares]

Nice list Setravis,

Applaud.
I wished you had a list of long stocks under $5 though .

Ares

[setravis]

Today's notes.......Take a look at you all !

Another reverse splitter BJCT which is being moved up pre-earnings announcement........

CCEL.......Vegas buy **Alert**    Double Bottom

Look @ also.......
TAOL.OB
VGNI.OB
VRA

[setravis]

7 Stocks You Need to Know for Wednesday


Here are 7 stocks for traders for Wednesday from TradingMarkets.com:
Excel Maritime Carriers (NYSE:EXM) missed earnings after the close on Tuesday; analysts were looking for $0.64 EPS, but EXM only announced $0.61. EXM's PowerRating is 7.

Medtronic (NYSE:MDT) beat earnings expectations, announcing $0.66 EPS over an expected $0.62 EPS. MDT's PowerRating is 7.

Dick's Sporting Goods (NYSE:DKS) announces earnings before the bell on Wednesday; look for $0.37 EPS. DKS's PowerRating is 4.

Analysts are looking for Eaton Vance (NYSE:EV) to report $0.21 EPS before the market opens on Wednesday morning. EV's PowerRating is 4.

Gamestop (NYSE:GME) reports quarterly earnings tomorrow before the market opens, with analysts looking for $0.16 EPS. GME's PowerRating is 4.

Target (NYSE:TGT) should announce $0.71 EPS when the company reports earnings before the bell on Wednesday morning. TGT's PowerRating is 5.

Abercrombie & Fitch (NYSE:ANF) reports Wednesday after the bell, so watch for heightened price action and volatility ahead of the close. ANF's PowerRating is 5.

[setravis]

Top Stories.......


Grant Life Sciences Stock Soars on Patent
Award for Cervical Cancer and HPV Diagnostics
Shares of Grant Life Sciences (GLIF) soared in Monday's session after
receiving notice of a U.S. patent award on Tuesday, September 11, for
"Peptides from E7 Protein of Human Papilloma Viruses 16 and 18 for
detecting and/or Diagnosing Cervical and Other Human Papilloma Virus
Associated Cancers." Hun-Chi Lin, Ph.D., Grant's President and Chief
Scientist explained, "This patent would protect our investment to date
in the development of our serum-based test for cervical cancer and allows
us to move forward confidently in seeking an appropriate development-
and-commercialization partner." Cervical cancer is predominantly
caused by human papillomavirus or HPV. Today, approximately 60 million
pap tests are performed annually in the United States, and an additional
60 million Pap Tests are performed annually in the rest of the
world, mainly in Canada, Western Europe and Japan. It is estimated
that outside of the United States, Canada, Western Europe and Japan,
approximately 1.7 billion women do not undergo regular cervical cancer
testing. In many cases, this scarcity of testing is the result of a lack of
economic resources. Pap Tests are the most common method for diagnosing
cervical cancer, but they have some significant shortcomings
that include false positive results and failure to diagnose cervical cancer
or pre-cancerous conditions in approximately 30% to 60% of cases. Pap
Tests are also unable to detect the presence of adenocarcinoma, a more
virulent cancer that stems from cervical cells with glandular or secretory
properties. The Company's non-invasive technology is used to detect
specific cervical cancer-causing proteins. The test utilizes antibodies
against these cancer-causing proteins for detection and once fully validated,
would serve as a low-cost complementary screen to existing Pap
technology. The test kit will contain the required container and reagents,
with a color change that indicates the presence of "detector" antibodies
that recognize the cancer-causing proteins. According to a New York
Times article on January 16, 2007, "The Pap smear, an annual ritual for
many women and the mainstay of cervical cancer prevention for more
than half a century, may start to fade in importance. Newer tests that
detects human papillomavirus, or HPV, which causes cervical cancer,
is starting to play a bigger role in screening." Currently, there are no
other companies developing a protein-based screening test that detects
antibodies to cervical cancer, but Grant will compete with HPV Tests in
the market. Manufacturers of HPV Tests include Digene Corporation,
Ventana Medical Systems (VMSI), Roche Diagnostics, Abbott Laboratories
(ABT), and Bayer Corporation (BAY). Grant's patented technology
may prove valid in the future to develop rapid tests for other diseases
and cancers. The Company also has exclusive worldwide rights to diagnostic
devices for HIV-1, HIV-2 and dengue fever. At June 30, 2007,
the Company had an accumulated deficit of $16.7 million and cash on
hand of $301,000.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


EntreMed Presents Data from Ph II
Trial of MKC-1 in Metastatic Breast Cancer
EntreMed, Inc. (ENMD) presented interim results for its Phase 2 clinical
study of MKC-1 in patients with metastatic breast cancer (MBC). The
study is being conducted at multiple centers across the United States
to evaluate the safety and efficacy of MKC-1 in metastatic breast cancer
patients who have failed therapy with anthracyclines and taxanes.
Results from the first stage of the single-agent study demonstrate that
orally-administered MKC-1 is well-tolerated without evidence of cumulative
toxicity in anthracycline/taxane refractory metastatic breast cancer
patients. Of the 35 evaluable patients, one complete response, two partial
responses, and three stable diseases of greater than four months
were observed. This study is continuing to enroll up to 53 evaluable
patients to confirm safety and assess the extent of objective responses
in this patient population.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


RadiSys Signs a Definitive
Agreement with Intel Corporation
RadiSys Corporation (RSYS) and Intel Corporation announced that
they have signed a definitive agreement for Intel to sell certain assets
of its modular communications platforms business to RadiSys. The acquisition
will further RadiSys' global leadership position in ATCA platforms
and solutions for telecommunication equipment manufacturers
worldwide and is expected to close in September, subject to normal
closing conditions. The consideration for this transaction will consist of
a purchase price of $25 million plus $6.75 million of inventory and other
considerations. RadiSys expects the transaction to add at least $50 million
of ongoing revenue per year once integrated into RadiSys' operations.
The two companies will be working together during the coming
months to seamlessly transition the assets in order to continue to offer
high quality service and support to all customers. A significant number of
the employees associated with these product lines, including engineering,
product testing/validation, operations and marketing personnel are
expected to accept offers from RadiSys and transition with the product
lines. Products associated with the sale include ATCA compute and
packet processing blades, ATCA chassis, and Chassis Management
Hardware and Software Modules, AMC module as well as cPCI blades,
cPCI chassis, and other legacy systems products.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Accentia Announce Evidence that
Chronic Sinusitis Is Caused by Fungus
Accentia Biopharmaceuticals (ABPI) announces evidence that most,
if not all cases of chronic sinusitis (CS), are due to a fungal-induced
inflammation as originally proposed by investigators at the Mayo Clinic.
The data were collected as part of the Company's ongoing pivotal
Phase 3 clinical trial for its lead pharmaceutical product, SinuNase(TM),
an intranasal formulation of the antifungal amphotericin B 0.01% suspension.
In order to be enrolled in the clinical trial, patients must have
had well-documented CS based on a history of the requisite symptoms,
nasal endoscopy findings, and CT scan demonstrating characteristic
mucosal changes in the sinuses. At the time of enrollment, all patients
have had nasal mucin collected. Subsequently, these specimens are
being tested for eosinophilic major basic protein (eMBP). In the first fifty
specimens now analyzed, all have been positive for eMBP, a toxic protein
released by inflammatory cells in response to fungi. The Company
believes that these findings strongly support a fungal-induced inflammation
as the cause of CS. SinuTest(TM), the diagnostic used to measure
eMBP in the nasal mucin, is a patented technology developed at the
Mayo Foundation for Medical Education and Research. The technology
is exclusively licensed to IMMCO Diagnostics, which has an exclusive
commercialization agreement with Accentia Biopharmaceuticals. The
Company believes that SinuTest will be a useful adjunct for identification
of patients who are suspected of having CS and who may be candidates
for treatment with SinuNase, assuming FDA approval.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Tri-S Security Awarded $13M Contract for
South Carolina w/Dept of Homeland Security
Tri-S Security Corp. (TRIS) announced that its wholly-owned subsidiary,
Paragon Systems, Inc., has been awarded a new contract with the U.S.
Department of the Homeland Security, for the State of South Carolina,
for $13.0 million. Paragon will begin the contract October 1st, 2007 and
the contract will run for five years at an estimated $2.6 million per year.
Paragon will provide security for federal government facilities throughout
the state of South Carolina. Over 100 armed security guards will be
deployed throughout the state.

[setravis]

▲TOP NEWS GAINERS.......

SYMBOL  CLOSE  %GAIN  VOLUME  NEWS
GBNS $0.074 640.00 817,800 Acquisition of Energetics, Inc. in Fort Worth, Texas
RENG $0.180 100.00 396,500 Signs LOI with Minera Del Pacifico S.A. to Acquire Mining Assets
KMA $5.810 66.48 6,081,400 Agreement to Be Acquired by Humana $6.20 Pr/Sh Cash and $50 Debt
GTEM $0.140 47.37 1,040,500 Jonathan Leinwand Replaces Peter Khoury as CEO
XTLB $1.740 28.89 1,183,000 Begins Ph Iib Clinical Trial of Bicifadine
TEGR $0.200 17.65 159,000 $1M Sale of Unregistered Common Stock to Esterna, Ltd. in Cyprus
NPLA $1.750 15.89 141,700 Customer Agrees to Purchase 1M thiNcoder Rotary Switches
ABPI $2.760 10.84 515,800 Announce Evidence that Chronic Sinusitis Is Caused by Fungus
PEFF $0.440 10.00 266,800 Enters AgreementWith a Global Contract Manufacturer
ARIA $4.950 4.65 895,100 FDA SPA Agreement for Ph 3 Trial of Deforolimus in Metastatic Sarcomas
OPNT $10.900 4.11 198,500 Subsidiary Wins Naval Indefinite Delivery/Indefinite Quantity Contract
ANX $2.380 2.59 966,000 FDA Approves NDA Plan for ANX-514 Formulation of Docetaxel
RSYS $11.470 1.59 241,700 Sign Definite Agreement with Intel Corporation

[setravis]

TOP STORIES.......


Flamel Enters into Development
and License Agreement With Wyeth Pharm
Flamel Technologies (FLML) announced that it has entered into a development
and license agreement with Wyeth Pharmaceuticals, a division
of Wyeth (WYE). The agreement is for the development and licensing of
a marketed protein to be delivered using Flamel's Medusa technology.
Flamel will receive an upfront payment and potential development fees,
milestones and royalty payments, the terms of which are not disclosed.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


DivX Announces Licensing
Agreement With QUALCOMM
DivX, Inc. (DIVX) announced a licensing agreement allowing QUALCOMM
to include DivX(R) technology in a range of QUALCOMM videoenabled
chipsets. This agreement will potentially allow consumers to
access high-quality DivX video on a wide range of mobile devices powered
by QUALCOMM's chipsets.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Rochester Medical Announces
Positive Results from Clinical Study
Rochester Medical Corporation (ROCM) publicized results from a significant
clinical study which further demonstrates the effectiveness of
its proprietary Infection Control Technology. The study concluded nitrofurazone-
impregnated urinary catheters, which were manufactured by
ROCM, reduced the incidence of catheter-associated bacteriuria and
funguria in adult trauma patients, reducing the need to change or prescribe
new antimicrobial therapy.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Vision-Sciences Receives Clearance
From FDA to Market New Line of EndoScopes
Vision-Sciences (VSCI) announced that it has received 510(k) clearance
from the U.S. Food and Drug Administration to market the Company's
new line of advanced digital, video-based flexible endoscopes, which
come with an integrated "built-in" light source, eliminating the need for a
separate camera head, light cable and optical coupler.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Novavax Announce that Candidates
Emerge for Varicella Zoster Virus Vaccine
Novavax, Inc. (NVAX) announced that several candidates have
emerged from an ongoing discovery program to create a novel vaccine
for preventing disease associated with the Varicella Zoster Virus (VZV)
in older adults. These candidates have met certain significant scientific
criteria established by the Company and are now targeted for pre-clinical
development.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


Radyne Business Unit
Awarded $2.1 Million in Contracts
Radyne Corporation (RADN) announced that its AeroAstro business
unit was awarded contracts for two significant types of communication
equipment. AeroAstro received a Phase II contract to continue development
of a reconfigurable Digital Extra-Vehicular Activity Radio (DEVAR)
for NASA. AeroAstro was also awarded a $1.2 million contract for advanced
communications technologies. Under the NASA contract, Aero-
Astro is developing a state-of-the-art digital software-defined radio with
data transceiver capabilities for voice, telemetry, and video.

[setravis]

▲TOP NEWS GAINERS.......

SYMBOL   CLOSE   %GAIN   VOLUME   NEWS
SOLN $1.450 113.24 167,000 Appoints Colburn to Interim President/CEO
SNRNE $0.200 33.33 128,900 Q1 EPS (1c) vs (2c) EPS +50% Y/Y
VSCI $2.290 23.78 3,873,900 Receives Clearance From FDA to Market New Line of EndoScopes
ERFW $1.060 19.10 447,400 Announces Debt Payoff to GCA
CATT $7.550 17.24 327,300 Sees Q4 Revenues in Range of $9.5M to $10.5M
GPSN $0.110 15.79 1,631,100 To Acquire Business & Assets of Uplink Corp.
WRLS $6.310 15.57 673,900 Raises Full Year, Q4 Teleguard Revenue Guidance
INHX $1.490 13.74 560,100 Enters Into Exclusive Worldwide License Agreement With University of GA
SGMA $11.060 13.55 72,900 Q1 EPS 21c vs 7c EPS +200% Y/Y
FLOW $8.970 8.99 1,201,400 Northland Sec Ups to Outperform from Market Perform; Sets Tgt @ $11
FLML $9.920 8.53 2,189,900 Enters into Development and License Agreement With Wyeth Pharm
NVAX $3.660 7.39 1,046,300 Candidates Emerge for Varicella Zoster Virus Vaccine
DIVX $14.840 7.23 902,800 Announces Licensing Agreement With QUALCOMM

[setravis]

TOP STORIES.......

(MECA)
Magna Entertainment Announces
Reorganization; Tries to Get on the Right Track
Horse racing usually grabs the attention of most Americans three times
a year for a total period of 6.5 minutes which is the combined time it
takes for the horses to run the three legs of the Triple Crown. For the
more equestrian enthused, the Breeders' Cup has begun to supplement
their hankering for racing. For the racing fanatics, multiple races,
leagues, and variations in the lengths of races have emerged to meet
the demands of fans and gamblers alike. The fact remains, though,
that the industry has become increasingly ludicrous with the amount of
money associated with the sport. Everything from stud fees to horses
winnings have exploded over the past few years. Also increasing is the
amount of betting on the races. Pari-mutuel betting has become a big
business especially in the state of New York. That state government is
currently debating what to do with its ailing thoroughbred horse racing
franchise and if to allow Gov. Spitzer's recommendations on its administration
and oversight. Much like the state of New York's horse racing
and gambling business, Magna Entertainment Corp (MECA) is attempting
to restructure it business to minimize losses and attempt to become
profitable once again. Following the report of their second quarter earnings
on August 9th, the Company noted some drastic changes would be
implemented to maximize shareholder value. The Company engaged
Greenbrook Capital Partners Inc. to conduct a strategic review and also
noted that they would cease racing operations at their Austrian racetrack,
Magna Racino, at the end of its 2007 meet, relinquish their racing
license for Michigan Downs, and terminate their racetrack development
project in Dixon, California. The Company announced during Thursday's
session the results of the strategic review. The plan called for adopting
a strategy which would eliminate the Company's debt by December of
2008 through the divesture of assets that were expected to generate
$600M-$700M. It was also noted that the Company would enter into
strategic transaction involving their racing, gaming, and technology operations
along with a possible equity issuance, likely in 2008. To help
fund the Company through its execution of the plan to become debt
free, the Company announced a total of $100M in financing consisting
of a $20M PIPE with Fair Enterprise Limited, and an $80M short term
bridge loan from a subsidiary of MI Developments Inc. (MIM), which
Frank Stronach serves as Chairman of the Board. Also of note was
the strategic review done by Greenbrook Capital Partners is owned by
MECA's ex-CEO and president, Tom Hodgson. In the press release announcing
Hodgson's departure in March of 2006, Stronach stated, "Tom
Hodgson, our current President and CEO, joined MEC in early 2005
to develop and implement the Company's recapitalization plan which
was announced in July 2005. Under his leadership, the recapitalization
plan has progressed well. The Board has decided that, going forward,
MEC should seek a CEO with in-depth knowledge and experience in
the horseracing and gaming industry who can lead the Company in fully
exploiting its opportunities in this sector." Reading between the lines
in a speculative nature, it seems that Hodgson was in the process of
recapitalizing and reorganizing the Company, was interrupted by the
Board and possibly more so by Stronach, who was then appointed interim
CEO, and now needs Hodgson's help again in reorganizing the
Company and has put up his own money to pay for his mistake. Again,
this is purely speculative and just one reader's take on the news but
could be right on the money considering Stronach's multiple changing
of CEO's in his companies. In any event, it seems some mistakes were
made and the overall horse racing/gambling market hasn't grown to the
extent to what the Company originally thought. If they are successful in
shedding their debt, it could save the Company some $60M in interest
expense which was how much the Company paid in fiscal year 2006,
but top line numbers will obviously take a hit following disposal of revenue
producing assets. The trade off seems necessary to become cash
flow positive. Either way, shares gained 20% on 800,000 shares traded,
and with that kind of following and movement, someone feels the Company
could be on the right track. Investors would be wise to watch.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>


(ADLR)
Adolor Reports the FDA Needs More
Time to Review Clinical Hold on Entereg(R)
Shares of Adolor Corporation (ADLR) declined today after the FDA said
it needed more time to complete its review of the submissions for the
release of the clinical hold on Entereg(R)(alvimopan). As a result, the
clinical hold for all alvimopan Investigational New Drug Applications
(INDs) remains in effect. The FDA did not indicate a time frame within
which its review would be completed. Adolor and its collaboration partner,
GlaxoSmithKline PLC (GSK), are seeking approval of alvimopan,
which is used for managing gastrointestinal side effects associated with
opioid use. Opioid analgesics, such as morphine, produce pain relief
by blocking pain signals through stimulation of opioid receptors located
on the surface of the nerves that transmit these signals. Because
there are opioid receptors also present in the gastrointestinal (GI) tract,
when opioids bind to these receptors, they can disrupt normal GI function
that allows for the passage of food through the GI tract and, consequently,
can cause patients to experience significant discomfort and
pain. These GI side effects include constipation, bloating, nausea and
vomiting. Entereg is also currently in late stage development to manage
postoperative ileus, a negative gastrointestinal side effect following
bowel resection surgery. Preliminary Phase III long-term safety results
of alvimopan in patients taking opioids for chronic non-cancer pain and
experiencing opioid-bowel dysfunction (OBD), showed an increase in
myocardial infarctions as compared with patients treated with placebo.
The preliminary results also showed an imbalance in the incidence of
neoplasms (benign, malignant, skin cancers and unspecified, including
polyps) and an increase in the incidence of fractures in patients receiving
Entereg, compared to placebo. The clinical hold previously forced
the Company to disband its sales force of approximately 35 people and
implement other workforce reductions. The Company's deficit accumulated
through June 30, 2007, was approximately $401.3 million, and
Adolor expects to continue to incur substantial losses in future periods.
Cash, cash equivalents and short-term investments were $158.3 million.
Progenics Pharmaceuticals, Inc. (PGNX) is developing methylnaltrexone
for the treatment of opioid-induced constipation without interfering
with pain relief. Progenics and Wyeth (WYE) are conducting two global
phase 3 clinical trials and targeting an NDA submission in early 2008.
There are also products on the market for use in treating irritable bowel
syndrome which may be evaluated for utility in opioid induced bowel
dysfunction. It is important to note that Glaxo has the right to terminate
the collaboration agreement with Adolor for safety related or adverse
regulatory events. Adolor's current revenues are derived from its agreement
with Glaxo. Adolor also has a number of discovery and clinical
research programs focused on the identification of novel compounds for
the treatment of pain. The Company's pain research efforts are focused
on designing small molecules for the development of medications that
produce pain relief equal to or superior to traditional narcotics, while
reducing or eliminating typical narcotic side effects. Brean Murray upgraded
ADLR yesterday to hold from sell, citing valuation.

[setravis]

▲TOP NEWS GAINERS.......

SYMBOL   CLOSE    %GAIN    VOLUME    NEWS
PLKT $0.730 35.19 527,200 2M in Private Placement Secured
MECA $2.230 19.89 810,600 Announces Short-Term Bridge Loan with MI Developments
EPM $2.580 18.89 278,000 Proved Reserves Increase 270% During Fiscal 2007
KAD $0.960 15.66 220,500 Completes Sale of Durable Medical Equipment Locations for $7.7M
GLOB $1.380 8.66 191,100 Wyndgate Tech Division Licenses Safe Trace Software to Cardio Center
NNBR $10.400 5.58 105,000 BoD Authorizes New Share Repurchase Program
WATG $6.320 5.33 57,000 Withdraws 6.5M Share Offering Based on Outlook
WX $27.470 4.93 1,488,900 Merrill Lynch Starts @ Buy; Sets Tgt @ $33
SCLD $1.370 3.79 289,700 Q3 EPS (5c) vs (46c) EPS +89% Y/Y
SPNC $14.670 2.44 414,500 To Appeal Decision in Patent Litigation
NTRZ $1.420 1.43 902,400 Baby Cereal Business Expands with the Addition of Two New Customers
SPPI $4.520 1.12 147,000 FDA Accepts ISO-Vorin Amendment; Action Date Set at 1/11/08
NR $5.540 1.09 864,300 To Acquire SEM Construction Company in Colorado for $21.3M